Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Alpharadin: Additional Phase II data

Additional data from a European Phase II trial (BC1-02)

Read the full 99 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE